论文部分内容阅读
作者注意到加拿大Quebec 省出血性中风比例增加,估计与阿斯匹林有一定关系。最近,主要参阅了近日的两篇临床试验报道,预防心肌梗塞首选阿斯匹林的讨论很多。两项研究阿斯匹林的预防效果不同,且与出血性中风程度的相关性也不同,这可能与研究设计不一和两组人群不同有关。英国医师发现阿斯匹林使用与否对出血性中风发生的例数无差别(相对危险RR=1.1)。美国医师的健康研究却表明用阿斯匹林与服安慰剂相比较,出血性中风增加1倍(23:12,RR=2.1 4,P<0.06)。从初级(primary)和二级(secondary)阿斯匹林预防心肌梗塞与中风效果的大量临床研究可评价阿
The authors note an increase in the proportion of hemorrhagic strokes in Quebec, Canada, which is estimated to be related to aspirin. Recently, the main reference to two recent clinical trials reported that the prevention of myocardial infarction preferred aspirin a lot of discussion. In both studies, aspirin has different prophylactic effects and is associated with a different degree of hemorrhagic stroke, which may be related to different design studies and differences between the two groups. British physicians found no difference in the number of cases of hemorrhagic stroke with or without aspirin (relative risk RR = 1.1). American physicians’ health studies have shown that hemorrhagic stroke is doubled with aspirin (23:12, RR = 2.1 4, P <0.06) compared with placebo. A large number of clinical studies to prevent primary myocardial infarction and stroke from primary and secondary aspirin can be evaluated